Cytosorbents Corp
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
In accordance with Section 13 or 15(d) of the Exchange Act, CytoSorbents Corporation has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on this 29th day of March, 2026.
| CYTOSORBENTS CORPORATION | |
| By: | /s/ Dr. Phillip P. Chan |
| Dr. Phillip P. Chan | |
| Chief Executive Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | | Title | | Date |
|---|---|---|---|---|
| /s/ Dr. Phillip P. Chan | Chief Executive Officer (Principal | March 29, 2026 | ||
| Dr. Phillip P. Chan | Executive Officer) and Director | | ||
| | ||||
| /s/ Peter J. Mariani | Chief Financial Officer | March 29, 2026 | ||
| Peter J. Mariani | (Principal Financial and Accounting Officer) | | ||
| | ||||
| /s/ Michael G. Bator | Chairman of the Board | March 29, 2026 | ||
| Michael G. Bator | | |||
| | ||||
| /s/ Alan D. Sobel | Director | March 29, 2026 | ||
| Alan D. Sobel | | |||
| | ||||
| /s/ Edward R. Jones | Director | March 29, 2026 | ||
| Edward R. Jones | | |||
| | ||||
| /s/Jiny Kim | Director | March 29, 2026 | ||
| Jiny Kim | ||||
FINANCIAL STATEMENTS
| Page | |
| Report of Independent Registered Public Accounting Firm | F-2 |
|---|---|
| Consolidated Balance Sheets at December 31, 2025 and 2024 | F-4 |
| Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2025, and 2024 | F-5 |
| Consolidated Statements of Changes in Stockholders’ Equity for the years ended December 31, 2025, and 2024 | F-6 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2025 and 2024 | F-7 |
| Notes to Consolidated Financial Statements | F-8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.